Artículos de revistas sobre el tema "CML, TKI, AOEs, cytokines"
Crea una cita precisa en los estilos APA, MLA, Chicago, Harvard y otros
Consulte los 50 mejores artículos de revistas para su investigación sobre el tema "CML, TKI, AOEs, cytokines".
Junto a cada fuente en la lista de referencias hay un botón "Agregar a la bibliografía". Pulsa este botón, y generaremos automáticamente la referencia bibliográfica para la obra elegida en el estilo de cita que necesites: APA, MLA, Harvard, Vancouver, Chicago, etc.
También puede descargar el texto completo de la publicación académica en formato pdf y leer en línea su resumen siempre que esté disponible en los metadatos.
Explore artículos de revistas sobre una amplia variedad de disciplinas y organice su bibliografía correctamente.
Sicuranza, Anna, Ilaria Ferrigno, Elisabetta Abruzzese, Alessandra Iurlo, Sara Galimberti, Antonella Gozzini, Luigiana Luciano et al. "Pro-Inflammatory and Pro-Oxidative Changes during Nilotinib Treatment in CML Patients: Results of a Prospective Multicenter Front-Line TKIs Study (KIARO Study)". Blood 138, Supplement 1 (5 de noviembre de 2021): 1479. http://dx.doi.org/10.1182/blood-2021-152530.
Texto completoLevy, Moshe Yair, Lin Xie, Yuexi Wang, Frank Neumann, Shouryadeep Srivastava, Daniel Naranjo, Qisu Zhang y Mehul Dalal. "Real-World Comparisons of Cardiovascular Events between Different Tyrosine Kinase Inhibitors Among Patients with Chronic Myeloid Leukemia". Blood 132, Supplement 1 (29 de noviembre de 2018): 3567. http://dx.doi.org/10.1182/blood-2018-99-113490.
Texto completoKantarjian, Hagop M., Javier Pinilla-Ibarz, Philipp D. Le Coutre, Ronald Paquette, Charles Chuah, Franck E. Nicolini, Jane Apperley et al. "Five-year results of the ponatinib phase II PACE trial in heavily pretreated CP-CML patients (pts)." Journal of Clinical Oncology 35, n.º 15_suppl (20 de mayo de 2017): 7012. http://dx.doi.org/10.1200/jco.2017.35.15_suppl.7012.
Texto completoLevy, Moshe Yair, Lin Xie, Yuexi Wang, Frank Neumann, Shouryadeep Srivastava, Daniel Naranjo, Jing Xu, Qisu Zhang y Mehul Dalal. "Major Adverse Cardiac, Arterial Occlusive, and Venous Occlusive Events Among Chronic Myeloid Leukemia Patients Prescribed Ponatinib Vs Bosutinib". Blood 134, Supplement_1 (13 de noviembre de 2019): 4751. http://dx.doi.org/10.1182/blood-2019-129053.
Texto completoCortes, Jorge E., Jane Apperley, Elza Lomaia, Beatriz Moiraghi, Maria Undurraga Sutton, Carolina Pavlovsky, Charles Chuah et al. "OPTIC primary analysis: A dose-optimization study of 3 starting doses of ponatinib (PON)." Journal of Clinical Oncology 39, n.º 15_suppl (20 de mayo de 2021): 7000. http://dx.doi.org/10.1200/jco.2021.39.15_suppl.7000.
Texto completoCaocci, Giovanni, Olga Mulas, Elisabetta Abruzzese, Alessandra Iurlo, Imma Attolico, Sara Galimberti, Luigia Luciano et al. "Arterial Occlusive Events in Chronic Myeloid Leukemia Patients Treated with Ponatinib in the Real-Life Practice: Prophylaxis and Identification of Risk Factors". Blood 132, Supplement 1 (29 de noviembre de 2018): 3006. http://dx.doi.org/10.1182/blood-2018-99-111502.
Texto completoIto, Tomoki, Nobuhiko Uoshima, Yasuhiro Maeda, Masaaki Hotta, Hideaki Yoshomura, Shinya Fujita, Atsushi Satake et al. "Evaluation Of Large Granular Lymphocytes and Endothelial-Cell-Related Biomarkers In Patients With Chronic Myeloblastic Leukemia: Comparison Among 3 TKIs". Blood 122, n.º 21 (15 de noviembre de 2013): 5167. http://dx.doi.org/10.1182/blood.v122.21.5167.5167.
Texto completoJedema, Inge, Linda van Dreunen, Roelof Willemze y J. H. Frederik Falkenburg. "Treatment with Tyrosine Kinase Inhibitors May Impair the Potential Curative Effect of Allogeneic Stem Cell Transplantation." Blood 114, n.º 22 (20 de noviembre de 2009): 857. http://dx.doi.org/10.1182/blood.v114.22.857.857.
Texto completoStemhagen, Annette, Deyaa Adib, Stephanie Lustgarten, Lisa McGarry, Ruth Du Moulin y Sergio Santillana. "The OMNI patient registry: A prospective observational registry to assess vascular safety in patients with CML and Ph+ ALL treated with ponatinib." Journal of Clinical Oncology 35, n.º 15_suppl (20 de mayo de 2017): TPS7073. http://dx.doi.org/10.1200/jco.2017.35.15_suppl.tps7073.
Texto completoTruitt, Luke, Catherine Hutchinson, Karen Mochoruk, John F. DeCoteau y C. Ronald Geyer. "Chaetocin Anti-Leukemia Activity Against Chronic Myelogenous Leukemia Stem Cells Is Potentiated By Bone Marrow Stromal Factors and Overcomes Innate Imatinib Resistance". Blood 124, n.º 21 (6 de diciembre de 2014): 4517. http://dx.doi.org/10.1182/blood.v124.21.4517.4517.
Texto completoPulte, E. Dianne, Haiyan Chen, Lauren S. L. Price, Ramadevi Gudi, Hongshan Li, Olanrewaju O. Okusanya, Lian Ma et al. "FDA Approval Summary: Revised Indication and Dosing Regimen for Ponatinib Based on the Results of the OPTIC Trial". Oncologist 27, n.º 2 (1 de febrero de 2022): 149–57. http://dx.doi.org/10.1093/oncolo/oyab040.
Texto completoJalkanen, Sari, Satu Mustjoki, Kimmo Porkka y Jukka Vakkila. "Cytokine-Mediated Signaling Is Suppressed in Myeloid Cells and Enhanced in Lymphatic Cells in Patients with Chronic Myeloid Leukemia (CML) — Partial Normalization with Tyrosine Kinase Inhibitors." Blood 114, n.º 22 (20 de noviembre de 2009): 2180. http://dx.doi.org/10.1182/blood.v114.22.2180.2180.
Texto completoRouhimoghadam, Milad, Anthony D. Pomicter, Alexandria Van Scoyk, Greg Poffenberger, Ivaylo Kirov, Lyubomir G. Nashev, Helong Zhao, Martin Martinov y Michael W. Deininger. "Exploiting LY3009120 and Asciminib Combination to Target TKI-Resistant CML". Blood 138, Supplement 1 (5 de noviembre de 2021): 3600. http://dx.doi.org/10.1182/blood-2021-153353.
Texto completoKantarjian, Hagop M., Michael W. Deininger, Elisabetta Abruzzese, Jane Apperley, Jorge E. Cortes, Charles Chuah, Daniel J. DeAngelo et al. "Efficacy and Safety of Ponatinib (PON) in Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Who Failed One or More Second-Generation (2G) Tyrosine Kinase Inhibitors (TKIs): Analyses Based on PACE and Optic". Blood 136, Supplement 1 (5 de noviembre de 2020): 43–44. http://dx.doi.org/10.1182/blood-2020-133922.
Texto completoKuznetsova, Valeriya, Virginia Camacho, Sweta Patel, Victoria Matkins y Robert S. Welner. "Perturbed function of natural killer cells by inflammatory cytokines in chronic myeloid leukemia". Journal of Immunology 206, n.º 1_Supplement (1 de mayo de 2021): 57.06. http://dx.doi.org/10.4049/jimmunol.206.supp.57.06.
Texto completoHiwase, Devendra K., Deborah L. White, Jason A. Powell, Verity A. Saunders, Stephanie Zrim, Amity Frede, Mark Guthridge et al. "Blocking of Cytokine Survival Signals along with Intense Bcr-Abl Kinase Inhibition May Eradicate CML Progenitor Cells." Blood 114, n.º 22 (20 de noviembre de 2009): 3250. http://dx.doi.org/10.1182/blood.v114.22.3250.3250.
Texto completoBusch, Caroline y Helen Wheadon. "Bone marrow niche crosses paths with BMPs: a road to protection and persistence in CML". Biochemical Society Transactions 47, n.º 5 (24 de septiembre de 2019): 1307–25. http://dx.doi.org/10.1042/bst20190221.
Texto completoZhao, Helong, Anthony D. Pomicter, Anna M. Eiring, Anca Franzini, Jonathan Ahmann, Jae-Yeon Hwang, Anna Senina et al. "MS4A3 promotes differentiation in chronic myeloid leukemia by enhancing common β-chain cytokine receptor endocytosis". Blood 139, n.º 5 (3 de febrero de 2022): 761–78. http://dx.doi.org/10.1182/blood.2021011802.
Texto completoCortes, Jorge E., Dong-Wook Kim, Javier Pinilla-Ibarz, Philipp D. le Coutre, Ronald Paquette, Charles Chuah, Franck E. Nicolini et al. "Evaluation of the Benefit/Risk Profile of Ponatinib in CP-CML Patients over Time: 4-Year Follow-up of the Phase 2 PACE Study". Blood 126, n.º 23 (3 de diciembre de 2015): 5142. http://dx.doi.org/10.1182/blood.v126.23.5142.5142.
Texto completoJabbour, Elias J., Jorge E. Cortes, Moshe Talpaz, Michele Baccarani, Michael J. Mauro, Andreas Hochhaus, Timothy P. Hughes et al. "Long-Term Follow-up of the Efficacy and Safety of Ponatinib in Philadelphia Chromosome-Positive Leukemia Patients with the T315I Mutation". Blood 128, n.º 22 (2 de diciembre de 2016): 3067. http://dx.doi.org/10.1182/blood.v128.22.3067.3067.
Texto completoNievergall, Eva, Deborah L. White, Agnes S. M. Yong, Hayley S. Ramshaw, Samantha J. Busfield, Gino Vairo, Angel F. Lopez, Timothy P. Hughes y Devendra K. Hiwase. "Effective Elimination of CML Progenitor and Stem Cells Through Combination of α-CD123 Antibody-Dependent Cell-Mediated Cytotoxicity and Tyrosine Kinase Inhibitor Treatment". Blood 120, n.º 21 (16 de noviembre de 2012): 32. http://dx.doi.org/10.1182/blood.v120.21.32.32.
Texto completoHernesniemi, Sari, Jukka Vakkila, Kimmo Porkka y Satu Mustjoki. "Single-Cell Profiling of Aberrant Cytokine Signaling in Patients with Chronic Myeloid Leukemia (CML) at Diagnosis and during Dasatinib Therapy". Blood 112, n.º 11 (16 de noviembre de 2008): 4214. http://dx.doi.org/10.1182/blood.v112.11.4214.4214.
Texto completoHeld, Stefanie AE, Anita Bringmann, Annkristin Heine, Grethe Kock, Ruth-Miriam Körber, Nina Manon Seltmann y Peter Brossart. "Interferon Gamma (IFNγ) Interferes with the Effects of Tyrosine Kinase Inhibitors (TKI) In CML Cells." Blood 116, n.º 21 (19 de noviembre de 2010): 3393. http://dx.doi.org/10.1182/blood.v116.21.3393.3393.
Texto completoOkabe, Seiichi, Tetsuzo Tauchi, Yuko Tanaka y Kazuma Ohyashiki. "Interleukin 1 Beta As a Promising Therapeutic Target in ABL Tyrosine Kinase Inhibitor Resistant Chronic Myeloid Leukemia Cells". Blood 132, Supplement 1 (29 de noviembre de 2018): 4249. http://dx.doi.org/10.1182/blood-2018-99-114030.
Texto completoJabbour, Elias J., Michael W. Deininger, Elisabetta Abruzzese, Jane F. Apperley, Jorge E. Cortes, Charles Chuah, Daniel J. DeAngelo et al. "Dose Modification Dynamics of Ponatinib in Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML) from the PACE and Optic Trials". Blood 138, Supplement 1 (5 de noviembre de 2021): 2550. http://dx.doi.org/10.1182/blood-2021-146175.
Texto completoZhang, Bin, Yin Wei Ho, Tessa L. Holyoake y Ravi Bhatia. "Inhibition Of Microenvironmental Interleukin-1 Signaling Enhances TKI-Mediated Targeting Of Chronic Myelogenous Leukemia Stem Cells". Blood 122, n.º 21 (15 de noviembre de 2013): 512. http://dx.doi.org/10.1182/blood.v122.21.512.512.
Texto completoZhang, Bin, YinWei Ho, Tinisha McDonald, Allen Lin, David S. Snyder, Vu N. Ngo, Tessa L. Holyoake y Ravi Bhatia. "Role of Enhanced Microenvironmental Interleukin-1 (IL-1) Expression and Increased IL-1 Responsiveness in Persistence of Leukemia Stem Cells in TKI Treated CML Patients". Blood 124, n.º 21 (6 de diciembre de 2014): 4357. http://dx.doi.org/10.1182/blood.v124.21.4357.4357.
Texto completoZhao, Helong, Anthony D. Pomicter, Anna M. Eiring, Anca Franzini, Jonathan Ahmann, Jae-Yeon Hwang, Anna V. Senina et al. "MS4A3 Promotes Differentiation in Chronic Myeloid Leukemia By Enhancing Common β Chain Cytokine Receptor Endocytosis". Blood 138, Supplement 1 (5 de noviembre de 2021): 59. http://dx.doi.org/10.1182/blood-2021-151559.
Texto completoMustjoki, Satu, Peter Rohon, Katrin Rapakko, Sari Hernesniemi, Perttu Koskenvesa, Tuija Lundán y Kimmo Porkka. "Low or Undetectable Numbers of Philadelphia Chromosome Positive (Ph+) Leukemia Cells in the Primitive (CD34posCD38neg) Stem Cell Fraction in Chronic Myeloid Leukemia (CML) Patients during Tyrosine Kinase Inhibitor Therapy." Blood 112, n.º 11 (16 de noviembre de 2008): 1079. http://dx.doi.org/10.1182/blood.v112.11.1079.1079.
Texto completoKuznetsova, Valeriya, Sweta Patel, Francesca Luca, Virginia Camacho, Victoria Matkins y Robert S. Welner. "Perturbed function of natural killer cells by inflammatory cytokines in acute (AML) and chronic (CML) myeloid leukemias". Journal of Immunology 208, n.º 1_Supplement (1 de mayo de 2022): 62.04. http://dx.doi.org/10.4049/jimmunol.208.supp.62.04.
Texto completoHochhaus, Andreas, Jorge E. Cortes, Dong-Wook Kim, Javier Pinilla-Ibarz, Philipp D. le Coutre, Ronald Paquette, Charles Chuah et al. "Efficacy and Safety of Ponatinib in CP-CML Patients By Number of Prior Tyrosine Kinase Inhibitors: 4-Year Follow-up of the Phase 2 PACE Trial". Blood 126, n.º 23 (3 de diciembre de 2015): 4025. http://dx.doi.org/10.1182/blood.v126.23.4025.4025.
Texto completode Lavallade, Hugues, David Marin, Melanie Hart, Takuya Sekine, Ian Gabriel, Abdullah Alsuliman, Alexandra Bazeos et al. "Chronic Myeloid Leukemia Patients on Tyrosine Kinase Inhibitor Have Normal T Cell Responses to Vaccination but An Impaired IgM Humoral Response Associated with Loss of Discrete Memory B Cell Subsets",. Blood 118, n.º 21 (18 de noviembre de 2011): 3753. http://dx.doi.org/10.1182/blood.v118.21.3753.3753.
Texto completoThiant, Stephanie, Moutuaata M.Moutuou, Philippe Laflamme, Radia Sidi Boumedine, Fanny Larochelle, Dominique Leboeuf, Denis-Claude Roy y Martin Guimond. "Disruption of the Peripheral Lymphoid Niche Contributes to Lymphopenia in CML Patients Undergoing Imatinib Treatments". Blood 126, n.º 23 (3 de diciembre de 2015): 5165. http://dx.doi.org/10.1182/blood.v126.23.5165.5165.
Texto completoKalota, Anna y Alan M. Gewirtz. "Computationally Designed, Small Molecule Inhibitors of Tubulin Inhibit the Growth of Gleevec Resistant Chronic Myelogenous Leukemia Cells." Blood 108, n.º 11 (1 de noviembre de 2006): 2173. http://dx.doi.org/10.1182/blood.v108.11.2173.2173.
Texto completoGutknecht, Michael, Lisa Güttler, Mark-Alexander Schwarzbich, Julia Salih, Lothar Kanz, Helmut R. Salih, Susanne Malaika Rittig y Frank Grünebach. "Upregulation of Osteoactivin Upon Exposure to Tyrosine Kinase Inhibitors Impairs the T Cell Stimulatory Capacity of Monocyte-Derived Dendritic Cells". Blood 118, n.º 21 (18 de noviembre de 2011): 1112. http://dx.doi.org/10.1182/blood.v118.21.1112.1112.
Texto completoÅgerstam, Helena, Nils Hansen, Sofia Von Palffy, Carl Sandén, Kristian Reckzeh, Christine Karlsson, Henrik Lilljebjörn et al. "IL1RAP Antibodies Block IL1-Induced Expansion of Primitive CML Cells and Display Therapeutic Effects in Xenograft Models". Blood 128, n.º 22 (2 de diciembre de 2016): 1118. http://dx.doi.org/10.1182/blood.v128.22.1118.1118.
Texto completoRein, Lindsay A. M. y David A. Rizzieri. "A Phase I Trial of Incorporating Natural Killer (K-NK) Cells for Patients with Chronic Myeloid Leukemia (CML) and Molecular Residual Disease after Tyrosine Kinase Inhibitor (TKI) Therapy". Blood 136, Supplement 1 (5 de noviembre de 2020): 5. http://dx.doi.org/10.1182/blood-2020-142062.
Texto completoIlander, Mette Matilda, Ulla Olsson-Strömberg, Hanna Lähteenmäki, Tiina Kasanen, Perttu Koskenvesa, Stina Söderlund, Martin Hoglund et al. "Disease Relapse After TKI Discontinuation In CML Is Related Both To Low Number and Impaired Function Of NK-Cells:Data From Euro-SKI". Blood 122, n.º 21 (15 de noviembre de 2013): 379. http://dx.doi.org/10.1182/blood.v122.21.379.379.
Texto completoSweet, Kendra, Ehab L. Atallah, Jerry P. Radich, Mei-Jie Zhang, Eva Sahakian, Melanie Mediavilla-Varela, Alexis Vistocky et al. "Second Treatment Free Remission after Combination Therapy with Ruxolitinib Plus Tyrosine Kinase Inhibitors in Chronic Phase Chronic Myeloid Leukemia (CML)". Blood 138, Supplement 1 (5 de noviembre de 2021): 2555. http://dx.doi.org/10.1182/blood-2021-147954.
Texto completoAbrishami, Mahsa, Landon Pastushok, Karen Mochoruk, John F. DeCoteau y C. Ronald Geyer. "Synthetic Anti-IL3 Receptor Antibodies As Therapeutics to Block Innate Imatinib Resistance in Chronic Myelogenous Leukemia". Blood 124, n.º 21 (6 de diciembre de 2014): 4519. http://dx.doi.org/10.1182/blood.v124.21.4519.4519.
Texto completoNievergall, Eva, John Reynolds, Chung H. Kok, Dale Watkins, Mark Biondo, Samantha J. Busfield, Gino Vairo et al. "High Plasma Levels of TGF-α and IL-6 at Diagnosis Predict Early Molecular Response Failure and Transformation in CML". Blood 124, n.º 21 (6 de diciembre de 2014): 1788. http://dx.doi.org/10.1182/blood.v124.21.1788.1788.
Texto completoHayashi, Yoshiki, Hirohisa Nakamae, Takako Katayama, Takahiko Nakane, Hideo Koh, Mitsutaka Nishimoto, Mika Nakamae et al. "Immunoprofile of Patients with Chronic Myeloid Leukemia Treated with Imatinib, Nilotinib or Dasatinib",. Blood 118, n.º 21 (18 de noviembre de 2011): 3764. http://dx.doi.org/10.1182/blood.v118.21.3764.3764.
Texto completoMauro, Michael J., Jorge E. Cortes, Hagop M. Kantarjian, Neil P. Shah, Dale L. Bixby, Ian W. Flinn, Thomas O'Hare et al. "Ponatinib in Chronic-Phase Chronic Myeloid Leukemia Patients: Final Report from a Phase 1 Trial". Blood 128, n.º 22 (2 de diciembre de 2016): 3063. http://dx.doi.org/10.1182/blood.v128.22.3063.3063.
Texto completoToda, Jun, Michiko Ichii, Hirohiko Shibayama, Hideaki Saito, Yuichi Kitai, Ryuta Muromoto, Jun-ichi Kashiwakura et al. "Role of Signal Transducing Adaptor Protein-1 (STAP-1) in Chronic Myelogenous Leukemia Stem Cells". Blood 132, Supplement 1 (29 de noviembre de 2018): 4245. http://dx.doi.org/10.1182/blood-2018-99-113725.
Texto completoCortes, Jorge E., Jane Apperley, Andreas Hochhaus, Michael J. Mauro, Philippe Rousselot, Tomasz Sacha, Moshe Talpaz et al. "Outcome By Mutation Status and Line of Treatment in Optic, a Dose-Ranging Study of 3 Starting Doses of Ponatinib in Patients with CP-CML". Blood 136, Supplement 1 (5 de noviembre de 2020): 44–45. http://dx.doi.org/10.1182/blood-2020-135883.
Texto completoMackenzie, Ryan, Jennifer Snead, Jonathan VanDyke y Michael Deininger. "Defining Extrinsic Survival Pathways in CML Progenitor Cells." Blood 114, n.º 22 (20 de noviembre de 2009): 941. http://dx.doi.org/10.1182/blood.v114.22.941.941.
Texto completoHi Wase, Devendra K., Deborah L. White, Verity A. Saunders, Junia V. Melo, Sharad Kumar y Timothy P. Hughes. "Short –Term Intense Bcr-Abl Kinase Inhibition Is Adequate to Trigger Cell Death in CML Cell Lines but Not in CML-CD34+ Cells Unless They Are Growth Factor Deprived." Blood 112, n.º 11 (16 de noviembre de 2008): 1086. http://dx.doi.org/10.1182/blood.v112.11.1086.1086.
Texto completoGutknecht, Michael, Simone Joas, Lisa Güttler, Lothar Kanz, Helmut R. Salih, Frank Grünebach y Susanne M. Rittig. "Monocyte-Derived Dendritic Cells Induce Functionally Active Regulatory T Cells Upon Exposure to BCR-ABL Tyrosine Kinase Inhibitors." Blood 120, n.º 21 (16 de noviembre de 2012): 2156. http://dx.doi.org/10.1182/blood.v120.21.2156.2156.
Texto completoKreutzman, Anna, Peter Rohon, Edgar Faber, Karel Indrak, Vesa Juvonen, Veli Kairisto, Jaroslava Voglova et al. "Interferon Alpha Treated Patients with Chronic Myeloid Leukemia (CML) In Prolonged Complete Remission Have Increased Numbers of NK-Cells and Clonal Gamma-Delta T-Cells, and a Distinct Plasma Cytokine Profile." Blood 116, n.º 21 (19 de noviembre de 2010): 1201. http://dx.doi.org/10.1182/blood.v116.21.1201.1201.
Texto completoHerrmann, Oliver, Caroline CA Weßling, Michael Huber, Shaoguang Li, Tim H. Brümmendorf, Steffen Koschmieder y Mirle Schemionek. "Genetic Depletion of Fc Gamma Receptor 2b Affects CML Stem Cell Biology". Blood 124, n.º 21 (6 de diciembre de 2014): 4528. http://dx.doi.org/10.1182/blood.v124.21.4528.4528.
Texto completo